Table 3.

Subgroup analyses for BMD and fractures at various sites.

Outcomes	Comparisons	WMD or RR and 95% CI	P value	Heterogeneity (%)/P value	Interaction P value
Lumbar spine BMD	ED-71 vs placebo	2.40 (2.17–2.63)	<0.001	–	<0.001
	ED-71 vs ALF	1.92 (0.30 –3.54)	0.020	99.9/< 0.001
	ED-71 plus bisphosphonate vs bisphosphonate	0.78 (0.70–0.86)	<0.001	0.0/0.803
	ED-71 vs bisphosphonate	−0.96 (–3.07 to 1.15)	0.373	88.4/0.003
FN-BMD	ED-71 vs ALF	1.78 (0.18–3.38)	0.029	98.0/< 0.001	<0.001
	ED-71 plus bisphosphonate vs bisphosphonate	0.97 (–0.46 to 2.39)	0.185	73.1/0.054
	ED-71 vs bisphosphonate	–0.41 (–1.44 to 0.62)	0.435	75.6/0.043
Hip BMD	ED-71 vs placebo	0.00 (–0.19 to 0.19)	1.000	–	<0.001
	ED-71 vs ALF	1.81 (0.34–3.28)	0.016	99.9/< 0.001
	ED-71 plus bisphosphonate vs bisphosphonate	0.14 (0.06–0.22)	0.001	0.0/0.927
All osteoporotic fractures	ED-71 vs ALF	0.70 (0.54–0.89)	0.004	0.0/0.430	0.999
	ED-71 plus bisphosphonate vs bisphosphonate	0.69 (0.27–1.76)	0.438	–
	ED-71 vs bisphosphonate	0.73 (0.08–6.72)	0.781	–
Vertebral fracture	ED-71 vs ALF	0.71 (0.52–0.95)	0.021	0.0/0.952	0.252
	ED-71 plus bisphosphonate vs bisphosphonate	1.39 (0.45–4.27)	0.565	–
Nonvertebral fracture	ED-71 vs ALF	0.65 (0.31–1.35)	0.248	36.0/0.210	0.139
	ED-71 plus bisphosphonate vs bisphosphonate	0.09 (0.01–1.14)	0.063	–